Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Compugen ( (CGEN) ) has provided an announcement.
On August 6, 2025, Compugen Ltd. announced the distribution of its proxy statement to shareholders for the upcoming annual general meeting scheduled for September 16, 2025, in Israel. The meeting will address the election of seven directors, approval of compensation for incoming executives, and re-appointment of the company’s independent accounting firm. This event is significant for stakeholders as it involves key decisions on leadership and financial oversight, impacting the company’s strategic direction and governance.
The most recent analyst rating on (CGEN) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Compugen stock, see the CGEN Stock Forecast page.
Spark’s Take on CGEN Stock
According to Spark, TipRanks’ AI Analyst, CGEN is a Neutral.
The overall stock score is influenced significantly by the company’s financial performance and technical analysis. While strategic partnerships and improved cash flow management are promising, ongoing profitability challenges and valuation concerns weigh on the stock’s attractiveness.
To see Spark’s full report on CGEN stock, click here.
More about Compugen
Compugen Ltd. operates in the biotechnology industry, focusing on the development of therapeutic and diagnostic products. The company is engaged in the discovery and development of therapeutic proteins and monoclonal antibodies, with a market focus on immuno-oncology.
Average Trading Volume: 236,401
Technical Sentiment Signal: Strong Sell
Current Market Cap: $136.5M
See more insights into CGEN stock on TipRanks’ Stock Analysis page.